The Carpentier-Edwards Perimount aortic valve demonstrated an expected durability of 19 years in patients aged 50-65 years without age-related risk for SVD.
Does the Carpentier-Edwards Perimount bioprosthesis provide long-term valve durability in patients aged 50-65 years undergoing AVR?
The Carpentier-Edwards Perimount bioprosthesis demonstrates an expected durability of 19 years in patients aged 50-65 years, supporting its use as a long-term option in this demographic.
Absolute Event Rate: 0% vs 0%
In patients aged 50-65 years undergoing AVR with the Carpentier-Edwards Perimount bioprosthesis, the expected valve durability was 19 years. Age was not a significant risk factor for SVD within this age group. Patient selection and attention to timing of reintervention may be determinants of long-term outcomes.
Bourguignon et al. (Mon,) reported a other. The Carpentier-Edwards Perimount aortic valve demonstrated an expected durability of 19 years in patients aged 50-65 years without age-related risk for SVD.